St. Jude Revises Timeline For Quadripolar CRT-D Device
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical now hopes for FDA approval of its highly-anticipated Unify Quadra quadripolar cardiac resynchronization therapy defibrillator system by year-end, an update from initial company expectations for a mid-year U.S. launch.
You may also be interested in...
FDA Approves St. Jude’s Quadripolar CRT-D Device Following Delay
The approval is significant as it marks the entry of the first quadripolar pacing system into the U.S. market. But St. Jude may not get as big of a positive gain from the product as previously expected, analysts suggest.
St. Jude CEO Confident In PFO Device Despite Competitor’s Failure
St. Jude Medical remains confident in its development-stage patent foramen ovale closure device for prevention of strokes or migraines, despite the well publicized failure of competing PFO device developer NMT Medical, CEO Daniel Starks said.
St. Jude CEO Confident In PFO Device Despite Competitor’s Failure
St. Jude Medical remains confident in its development-stage patent foramen ovale closure device for prevention of strokes or migraines, despite the well publicized failure of competing PFO device developer NMT Medical, CEO Daniel Starks said.